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The vast majority of eukaryotic proteins are N-terminally modified by one or more processing
enzymes. Enzymes acting on the very first amino acid of a polypeptide include different pep-
tidases, transferases, and ligases. Methionine aminopeptidases excise the initiator methionine
leaving the nascent polypeptide with a newly exposed amino acid that may be further mod-
ified. N-terminal acetyl-, methyl-, myristoyl-, and palmitoyltransferases may attach an acetyl,
methyl, myristoyl, or palmitoyl group, respectively, to the -amino group of the target protein
N-terminus. With the action of ubiquitin ligases, one or several ubiquitin molecules are trans-
ferred, and hence, constitute the N-terminal modification. Modifications at protein N-termini
represent an important contribution to proteomic diversity and complexity, and are essential
for protein regulation and cellular signaling. Consequently, dysregulation of the N-terminal
modifying enzymes is implicated in human diseases. We here review the different protein N-
terminal modifications occurring co- or post-translationally with emphasis on the responsible
enzymes and their substrate specificities.
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1 Introduction
From the moment a eukaryotic nascent polypeptide emerges
from the ribosome, a machinery of different enzymes is in
place to modify its N-terminal (Nt) amino acid residue. These
modifications (Fig. 1) have evolved to substantially increase
the cellular protein repertoire. Despite the abundance of Nt-
modifications, the specific functions of N-terminally modify-
ing enzymes remain incompletely understood. Initiator me-
thionine excision by methionine aminopeptidases (MetAPs)
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is very common and essential, but not comprehended in
terms of its functional implications [1]. Another highly abun-
dant co-translational modification is Nt-acetylation catalyzed
by N-terminal acetyltransferases (NATs) [2]. The NATs also
carry outNt-propionylation, amuch rarer and less understood
modification [3]. Protein fatty acylation of the N-terminus
normally involves Nt-myristoylation catalyzed by N-terminal
myristoyltransferases (NMTs) [4]. Nt-palmitoylation is rarer
and is carried out by distinct enzymes, the N-terminal palmi-
toylacyltransferases (PATs) [5]. The abovementioned modifi-
cations mostly occur co-translationally, but the N-terminus
can also be post-translationally modified. Nt-methylation is
a common type of post-translational modification catalyzed
by N-terminal methyltransferases (NTMTs) [6, 7]. Addition-
ally, Nt-ubiquitylation has emerged as a new scarce mem-
ber of the Nt-modification family [8]. Together, the various
Nt-modifications have profound functional effects. The re-
sponsible enzymes act in more or less sequence specific
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Figure 1. Structural formulae of major N-
terminal protein modifications. The N-terminal
-amino group is (usually) positively charged
at neutral pH. The chemical character of
protein N-termini can be modified by, for
example: acetylation, propionylation, methy-
lation, myristoylation, palmitoylation or ubiq-
uitylation (attachment shown in red). The
responsible enzymes and their respective
donor molecules are listed. NATs, N-terminal
acetyltransferases; NPTs, N-terminal propi-
onyltransferases; NTMTs, N-terminal methyl-
transferases; NMTs, N-terminal myristoyltrans-
ferases; PATs, Palmitoylacyltransferases; CoA,
Coenzyme A;  denotes permanent positive
charge.
manners in order to establish specific functions to particular
substrate proteins.Wewill here review themajor co- and post-
translational protein Nt-modifications including their biolog-
ical impact. We will further address the current knowledge
of the responsible enzymes and their substrate sequence re-
quirements.
2 N-terminal methionine cleavage
When a nascent polypeptide emerges from the ribosomal exit
tunnel it is introduced to a set of different proteins. Amongst
them is MetAPs methionine aminopeptidases (MetAPs) [9],
destined to co-translationally remove the initiator methion-
ine (iMet) in the case of a favourable second amino acid.
Complete cleavage of the iMet is achievable when Ala, Cys,
Gly, Pro, Ser, Thr or Val sequesters the second position (Ta-
ble 1). These amino acids all have an uncharged side chain
with a radius of gyration of <1.29 A˚ as defined by Levitt
[10]. In contrast, there is a full iMet-retention when the sec-
ond residue belongs to any of the other naturally occurring
amino acids. These features make up the criteria for iMet re-
moval on a nascent polypeptide [1,10–14]. However, in some
cases the amino acid residue in the third position can in-
fluence the activity of MetAPs. For example, the iMet of the
-chain of Hemoglobin Long Island [15,16] and Hemoglobin
Marseille [17] is retained following His to Pro substitution
at position three, possibly due to steric hindrance. Some
actins constitute an exception to the general iMet exci-
sion pathway. For instance, mammalian cytoplasmic -actin
C© 2015 The Authors. PROTEOMICS Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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(Met-Glu-Glu-) has a large amino acid residue in the second
position and the iMet is not processed by the co-translationally
acting MetAPs. Instead, this actin is post-translationally pro-
cessed by an unidentified aminopeptidase [18].
The event of iMet removal is conserved throughout evolu-
tion [19] and is predicted to occur when the nascent polypep-
tide has reached a length of 20–40 amino acids [20–22]. It is
estimated that more than 50% of all proteins are subjected to
iMet removal [23]. Arfin et al. proposed a model for the sub-
families of MetAPs based on the catalytic cobalt-binding do-
main of the enzymes [24]. The updated version of this model,
based on additional sequence features like N-terminal exten-
sion, linker region and zinc finger domains, displays two
groups of MetAPs, namely MetAP1 andMetAP2. The former
is divided into four subgroups, Type 1a-d. Type 1a and 1c are
found in prokaryotes, while Type 1b, 1d and Type 2 MetAPs
are present in eukaryotes [19, 24–32]. Predictions on riboso-
mal binding of MetAPs suggest that one or several exposed
PXXPmotifs of the peptidases are involved in protein-protein
interactions [25, 26, 33].
Structural studies of humanMetAP1 andMetAP2 revealed
a potential difference in the substrate specificity of the respec-
tive catalytic sites due to more steric restrictions in MetAP1
[25]. This is supported by the finding that MetAP2, and not
MetAP1, is inhibited by the anti-angiogenic agent fumagillin
[32]. Growth studies in yeast have shown that the iMet pro-
cessing provided by MetAP1 and MetAP2 is essential since a
double deletion is lethal for yeast while the single deletions
are viable [30]. This strongly suggests that both enzymes, at
least in part, act on the same substrates in vivo. Significant
overlap in substrate specificity was also found for human
MetAP1 and MetAP2, although a significant preference of
MetAP2 for Met-Val- and Met-Thr- N-termini was observed
[34].
3 N-terminal acetylation
One of the most abundant protein modifications occurring
in eukaryotes isN-terminal acetylation (Nt-acetylation), where
an acetylmoiety is transferred fromacetyl-CoA to the-amino
group of a nascent polypeptide. TheNt-acetylome is estimated
to include 80–90% of soluble human proteins and 50–70%
of yeast proteins [35, 36]. N-terminal acetylation of a specific
protein can either be complete or partial, and in the latter
case the protein exists in both acetylated and non-acetylated
forms.
Traditionally, Nt-acetylation has been regarded as a co-
translational process taking place on a nascent polypeptide
when approximately 25–50 amino acids residues emerge
from the ribosomal exit tunnel [37, 38]. In addition, there
are examples of post-translational Nt-acetylation of proteins
[39, 40]. The acetylation process neutralizes the positive
charge normally associated with the free -amino group, and
thereby efficiently blocks the -amino group for further ion-
ization and other modifications (Fig. 1).
Nt-acetylation is catalyzed by a set of enzymes, the N-
terminal acetyltransferases (NATs). The NATs are members
of the GNAT protein superfamily [41], all containing the con-
sensus acetyl-CoAbinding sequence (Q/R)XXGXX(G/A) [42].
The enzymatic machinery is conserved from lower to higher
eukaryotes suggesting a comparable system forNt-acetylation
[43]. The various NATs display different substrate specifici-
ties (Table 1), largely attributed to the identity of the first
two amino acids in the polypeptide sequence [44]. However,
residues beyond position seven may have an influence [35].
The majority of Nt-acetylation is catalyzed by NatA, NatB
and NatC. Here, the NAT-function is dependent upon com-
plex formation between a unique catalytic subunit and one
or two auxiliary subunits. The auxiliary subunits have vari-
ous functions including ribosomal anchoring [45, 46]. NatA,
the major NAT-complex, is composed of the catalytic subunit
Naa10 and the regulatory subunit Naa15 [47–49]. The NatA
complex acetylates N-termini starting with Ala, Cys, Gly, Ser,
Thr or Val following iMet removal [35, 44]. In the absence
of Naa15 the substrate specificity profile of Naa10 changes
towards acidic N-termini [50]. The NatB complex, which is
composed of the catalytic Naa20 and auxiliary Naa25 sub-
units [51, 52], acetylates Met-Asn-, Met-Asp-, Met-Gln- and
Met-Glu-starting N-termini [18, 44, 53]. NatC, on the other
hand, is composed of the three subunits Naa30, Naa35 and
Naa38. Naa30 is responsible for the acetylation reaction, but
all subunits appear to be required for NatC-activity [54]. The
activity of NatC is directed towards the iMet when followed
by a hydrophobic second residue, that is Ile, Leu, Phe, or Trp
[18, 44, 55, 56].
Three additional NATs (NatD, NatE, and NatF) have
been identified thus expanding the NAT-family substrate
repertoire. The evolutionarily conserved acetyltransferase
NatD displays a limited substrate profile by N-terminally
acetylating only histones H2A (Ser-Gly-Arg-) and H4 (Ser-
Gly-Gly-) [57, 58]. However, recent data suggest that NatD
may share some Ser-Gly- starting substrates with NatA [59].
NatE was first reported when yeast Naa50 was found to be
physically associated with the NatA complex, but no impact
on NatA-activity was observed [45]. In vitro studies revealed
that human Naa50 is able to perform Nt-acetylation of a
Met-Leu- substrate, and the activity was termed NatE [60].
The substrate specificity profile of NatE was later expanded
to include Met-starting N-termini: Met-Ala-, Met-Lys-, Met-
Met-, Met-Phe-, Met-Ser-, Met-Thr-, Met-Tyr-, and Met-Val-
[50]. The evolutionary shift in the degree of Nt-acetylation
between yeast and human could partly be explained by the
presence of NatF (Naa60) in human (and other multicellular
eukaryotes). NatF acetylates Met-Lys- N-termini which are
rarely acetylated in yeast, in addition to Met-Ala-, Met-Gln-,
Met-Gly-, Met-Ile-, Met-Leu-, Met-Met-, Met-Ser-, Met-Thr-,
Met-Tyr- and Met-Val-. NatC, NatE and NatF thus have
partially overlapping substrate specificities [36]. Interest-
ingly, Aksnes and colleagues recently reported that NatF
is localized to the Golgi, where it specifically Nt-acetylates
transmembrane proteins, most likely in a post-translational
C© 2015 The Authors. PROTEOMICS Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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mode [61]. This study also uncovered that Nt-acetylation is
highly abundant among human transmembrane proteins.
Worth mentioning, the Nt-acetylation signatures are not
absolute. The specificity can be affected by downstream
residues and other determinants, such as secondary struc-
tures [18]. This could also explain the existence of both com-
plete and partial Nt-acetylation. Goetze et al. have shown that
Nt-acetylation is prevented when the nascent protein has a
Pro in the first or second position. Pro as a definite determi-
nant preventing Nt-acetylation is referred to as the (X)PX rule
[62]. No N-terminal deacetylase has been identified and thus
Nt-acetylation is considered irreversible.
The crystal structures of several NATs have been solved
[63–67], includingS. pombeNatA [65] andhumanNaa50/NatE
[64]. Structural variability between the two catalytic subunits
of NatA and NatE contributes to the substrate specificity.
Binding of the auxiliary subunit may introduce conforma-
tional changes in the active site of the catalytic subunit and
promote sequence-specific Nt-acetylation as seen in NatA
[65]. Recent evidence suggests that Nt-acetylation takes place
through an ordered ternary-complex (Bi-Bi) mechanism [64–
66,68]. Here, binding of acetyl-CoA induces rearrangements
in the NAT-enzyme, which subsequently increases the affin-
ity for the peptide substrate allowing the reaction to occur.
4 N-terminal propionylation
The N-terminal protein modification family was recently ex-
panded to include a new member, namely N-terminal pro-
pionylation (Nt-propionylation) (Fig. 1). Propionylated N-
termini were first discovered in human cells [69,70] and later
shown to occur in yeast, demonstrating that thismodification
is evolutionarily conserved [3].
Studies by Foyn and colleagues show that NATs may also
function as N-terminal propionyltransferases (NPTs), both
in vivo and in vitro. By challenging purified human Naa10,
Naa50, and NatA with propionyl-CoA they demonstrated that
all enzymes could indeed perform Nt-propionylation on sub-
strate peptides in vitro. The NPT-activity of purified Naa10
and Naa50 were far less efficient than their acetylation ac-
tivities using acetyl-CoA. Intriguingly, the NatA complex
performed Nt-acetylation and Nt-propionylation with simi-
lar rates, particularly for peptides substrate starting with Ser.
Furthermore, Nt-proteomics revealed that both yeast and hu-
manNatA complexes could performNt-propionylation in vivo
[3].
Since propionylation of protein N-termini was only re-
cently discovered, virtually nothing is known about its func-
tional importance. The cellular level of acetyl-CoA is 2-20-fold
higher compared to propionyl-CoA [71, 72]. This could ex-
plain the low detection rate of Nt-propionylated compared to
Nt-acetylated substrates. In addition, it is uncertain whether
Nt-propionylation occurs on specific substrates and conveys
a signal different from Nt-acetylation. The propionyl group
contains an additional methyl moiety as compared to acetyl
and this might result in additional bulkiness and hydropho-
bicity. Hitherto 18 proteins have been identified as being
Nt-propionylated, four of which are processed mitochondrial
proteins. This indicates a post-translational as well as a co-
translational mode for this modification [3, 69, 70].
5 N-terminal myristoylation and
palmitoylation
N-terminal myristoylation (Nt-myristoylation) refers to the ir-
reversible transfer ofmyristoyl (14-carbon saturated fatty acid)
from myristoyl-CoA to the N-terminal Gly of the target pro-
tein (Fig. 1). N-terminalmyristoyltransferase (NMT) catalyzes
the chemical reaction [4], following an ordered Bi-Bi reaction
mechanism [73–76]. Initially, this protein modification was
found to exist as a co-translational event, supported by the iso-
lation of myristoyl-labelled nascent polypeptide chains asso-
ciated with tRNA and the identification of NMT in the riboso-
mal subcellular fraction [77–80]. However, Nt-myristoylation
has been found to occur as a post-translational event as well,
mainly in apoptotic cells [81–83].
Prior to Nt-myristoylation, the iMet needs to be removed
byMetAP, thus exposing the consensus sequence recognized
by NMT. The consensus sequence has been revealed in the
context of several in vivo and in vitro studies [4,84]. Gly in the
first position is an absolute requirement. In the second posi-
tion a charged residue is favored, whereas aromatic residues
and Pro are prohibited. There are no special requirements
for the third position. Ala, Asn, Cys, Gly or Ser is allowed in
the fourth position while in position five Cys, Ser, or Thr is
preferred and Pro is prohibited.
Two isozymes of NMT, NMT1 and NMT2, have been iso-
lated and characterized [78, 85, 86]. The evolutionary con-
servation of both structure and substrate specificity (Table
1) [84, 86–92]. Human NMT1 and NMT2 possess approxi-
mately 77% amino acid sequence identity. The majority of
divergence between the two NMTs is seen in the N-terminal
domain, which is important for ribosomal binding [86, 93].
Both unique and overlapping substrate specificities are ob-
served between NMT1 and NMT2 within a given species
[86, 92, 94–96].
It is estimated that about 0.5% of cellular proteins are
Nt-myristoylated [97–101]. Different Nt-myristoylation pre-
diction tools exist, e.g. MYR Predictor [102] and Myristoyla-
tor [103]. Caution should be exercised because false-positive
and false-negative predictionsmight occur [104], thus demon-
strating the necessity of both in vivo and in vitro studies for
complete data [4]. Thinon et al. recently established a global
profile of the Nt-myristoylome in both normal and apoptotic
cells [105].
Unlike the immense amount of data on Nt-myristoylation,
far less is known about Nt-palmitoylation. Normally, the
palmitoyl group (16-carbon saturated fatty acid) is attached
to an internal Cys residue [106], but a few instances of palmi-
toylated N-termini have been uncovered. A study by Klauss
C© 2015 The Authors. PROTEOMICS Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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and Krause shows co-translational Nt-palmitoylation of GS,
the -subunit of the heterotrimeric G protein responsible for
activation of adenylyl cyclase. Here, a palmitoyl group from
palmitoyl-CoA is attached to the -amino group of the N-
terminal Gly residue (Fig. 1) [107, 108].
Interestingly, the secreted vertebrate signaling proteins
Hedgehog (Hh) and Sonic Hedgehog (Shh) have been found
Nt-palmitoylated at Cys, following cleavage of the N-terminal
signal sequence [5, 109]. Hhat, an N-terminal palmitoylacyl-
transferase (PAT) is suggested to palmitoylate Shh [110–113],
and thismodification constitutes an important regulatory fea-
ture for the strength of Shh signaling [114]. Hhat belongs
to the family of multipass transmembrane proteins termed
MBOAT (membrane-bound O-acyltransferase) [115] and acy-
lates Shh during its passage through the secretory pathway
[110]. Rasp, another member of the MBOAT family, is re-
sponsible for Nt-palmitoylation of the Hh and Spitz proteins
in D. melanogaster [111, 116, 117].
6 N-terminal methylation
N-terminal methylation (Nt-methylation) is a process by
which a methyl group is transferred from S-adenosyl methio-
nine (SAM) to the exposed N-terminal -amino group follow-
ing iMet cleavage. The existence of Nt-methylation has been
known for decades [6, 118–120], however its structural and
functional importance has only recently emerged [121–126].
The chemical consequence of Nt-methylation depends on
the degree of residue methylation. Monomethylation will
probably have a minor effect on the basicity of the -amino
group, by increasing the pKa slightly and cause some steric
hindrance thatmay reduce its reactivity. In contrast, trimethy-
lation (or dimethylation in the case of Pro) will have a pro-
found effect by generating a permanent positive charge on
the N-terminal amino group (Fig. 1). Consequently, the nu-
cleophilicity normally associated with the -amino nitrogen
is abolished [6]. Nt-methylation is assumed irreversible as no
N-terminal demethylase has been identified [7].
Recently, two independent studies finally identified the
first N-terminal methyltransferases (NTMTs). The ortho-
logues yeast Tae1 and humanMETTL11Awere reported to re-
spectively catalyze the stoichiometric Nt-methylation of the ri-
bosomal proteinsRpl12a/b andRps25a/b [127] andRCC1, RB
and SET [128]. To reflect their unique role in Nt-methylation
the enzymes were renamed NTMT1. NTMT1, which is a
member of the seven-beta-strand class I methyltransferase
family, is conserved across eukaryotes and have one close
human homologue. A study by Petkowski et al. confirmed
that NTMT2 displays N-terminal methyltransferase activity
as well [129].
The substrate consensus sequence for the eukaryotic
NTMTs was initially thought to be X-Pro-Lys-, where X can
be Ala, Pro or Ser (Table 1) [6]. Further in vitro studies have
shown that NTMT1 is somewhat promiscuous concerning
the identity of the first amino acid. A recombinant NTMT1 is
able to methylate RCC1 peptides as long as the first position
is not occupied by the acidic residues Asp or Glu, Trp, or
the hydrophobic residues Ile or Leu [128]. An expanded pep-
tide library methylation assay furthermore showed that the
presence of a Pro in the second position is not an absolute
requirement [130]. Efficient Nt-methylation requires Lys in
the third position, but can in rare cases be replaced by Arg
[125, 128, 130]. Taken together this implies that NTMT1 may
have a broader specificity than previously acknowledged, and
this could also be the case for NTMT2. Interestingly, it was
recently shown that CENP-A [125] and CENP-B [123] with the
Gly-Pro-starting N-termini are Nt-methylated in vivo.
Givenboth sequence and structural similarity [129], it is not
unreasonable to believe that NTMT1 and NTMT2 have sim-
ilar localization patterns and catalytic activities. In fact, both
enzymes are expressed at low levels and localizes predomi-
nantly to the nucleus [129]. In contrast, the enzymes display
different methylation mechanisms. NTMT1 is a distributive
trimethylase, which can mono-, di-, and trimethylate its sub-
strates whereas NTMT2 is primarily an Nt-monomethylase.
A synergistic NTMT mechanism has been proposed where
NTMT2 primes substrates for subsequent di- and trimethyla-
tion by NTMT1. Hence, NTMT2 would confer aid to NTMT1
when the substrate burden is too high [129].
7 N-terminal ubiquitylation
The addition of ubiquityl to a substrate protein proceeds
through a three-step process that is achieved by the combined
activity of ubiquitin activating (E1), conjugating (E2), and lig-
ating (E3) enzymes. Most commonly, ubiquityl is conjugated
to the -amino group of an internal Lys residue. N-terminal
ubiquitylation (Nt-ubiquitylation) refers to the addition of an
ubiquityl moiety to the free -amino group of the first residue
of a protein (Fig. 1). In both cases, ubiquitylmay serve as a tar-
get for polyubiquitylation, which is a well-known degradation
signal recognized by the proteasome [131,132].
An N-terminal residue was initially found by Breitschopf
et al. to act as a novel site for ubiquitylation when Lys replace-
ment in the protein MyoD did not significantly affect its sus-
ceptibility for either in vitro or in vivo ubiquitylation or degra-
dation [133]. The first direct evidence of Nt-ubiquitylation
came when MS analysis revealed that ubiquityl was indeed
fused to the N-terminal -amino group of HPV-58 oncopro-
tein E7 [134]. Previously, there had been strong indications
that a handful of proteins underwent degradation mediated
by Nt-ubiquitylation [135–141]. However, in these cases the
stability is presumably modulated through interplay between
ubiquitylation at theN-terminus and on internal Lys residues.
Seeing thatHPV-58 E7 is a naturally occurring lysine-less pro-
tein its degradation is more likely to be completely dependent
upon Nt-ubiquitylation.
The known substrates for Nt-ubiquitylation do not share
any homology in their N-terminal region [8]. Thus, it is not
unreasonable to consider that Nt-ubiquitylation is facilitated
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by several enzymes that provide different substrate specificity,
subcellular localization andmodes of regulation.Hitherto, E2
Ube2w [142,143] and E3 HUWE1 [144] are the only enzymes
with a reported ability to ubiquitylate the N-terminus of sub-
strates. HUWE1was shown to ubiquitylate the N-terminus of
lysine-less MyoD, but, interestingly, favors an internal Lys in
wild-type MyoD and leaves the N-terminus unubiquitylated
[144]. Ube2w, on the other hand, is able to successfully ubiq-
uitylate theN-terminus of a lysine-less version of Ataxin-3 and
Tau [142]. When comparing the active site of Ube2w to that of
classical E2s there are some distinctive differences. Together,
these features make the novel active site of Ube2wmore suit-
able to accommodate a neutral -amino group rather than
a positively charged Lys side chain [142, 143]. Interestingly,
Vittal et al. recently reported that Ube2w recognizes the pep-
tide backbone of unstructured N-termini, and that the pres-
ence of Pro in position two to four has an inhibitory effect on
Ube2w-activity [145].
Nt-ubiquitylation is not to be confused with the N-end
rule, which relates the in vivo half-life of a protein to the iden-
tity of its N-terminal residue. Specific E3 ubiquitin ligases,
called N-recognins, target protein substrates through their
destabilizing N-terminal residues for polyubiquitylation and
proteasomal degradation [146, 147]. In eukaryotes, these N-
terminal degradation signals, called N-degrons, comprise a
destabilizing N-terminal residue as well as an internal ly-
sine(s) residue within an unstructured (flexible) segment of
the protein’s polypeptide chain [148]. Primary destabilizing
residues are positively charged (basic) and bulky hydropho-
bic N-terminal residues that are directly recognized by N-
recognins [149,150]. A recent study reported that an unacety-
lated N-terminal Met could also act as a primary destabiliz-
ing residue if this Met is followed by a hydrophobic residue
[151]. The secondary and tertiary destabilizing residues Asn,
Asp, Cys, Gln, and Glu require preliminary enzymatic mod-
ifications, including Nt-deamidation and Nt-arginylation, be-
fore the recognition by N-recognins of the N-end rule path-
way [149, 150]. Yet another mechanistically distinct branch
of the N-end rule pathway was identified in 2010 [152]. In
this branch, termed the Ac/N-end rule pathway (the previ-
ously known branch was termed the Arg/N-end rule path-
way), destabilizing N-terminal residues (those that can be
Nt-acetylated by NATs) are recognized by distinct ubiquitin
ligases (Doa10 and Not4) termed Ac/N-recognins [152, 153].
The N-end rule pathway continues to be deciphered and as
novel features are revealed, the framework of this proteolytic
system keeps expanding (recommended in-depth reviews for
further reading [147, 149, 150, 154]).
8 Biological functions of N-terminal
modifications
While the presence and abundance of Nt-modifications have
been thoroughly demonstrated during the last decades, the
functional roles of these modifications are now beginning to
emerge. Very recent studies demonstrated that iMet cleav-
age and Nt-acetylation might be important players in the
expanded N-end rule pathway, linking the identity of the
protein N-terminus to its in vivo stability [151–153, 155].
Nt-acetylation may further be important for targeting spe-
cific proteins to intracellular membranes like the Golgi-
membrane or the inner nuclear membrane [156–158]. In a
global survey, N-termini of cytosolic proteinswere found to be
more prone to be Nt-acetylated as compared to secreted pro-
teins [159]. Interestingly, mutating the N-termini of specific
proteinswith signal sequences to becomeNt-acetylated inhib-
ited their post-translational translocation to the endoplasmic
reticulum. This suggested that Nt-acetylation prevents this
type of subcellular targeting. In some cases, Nt-acetylation
is crucial for proper protein complex formation [160, 161].
A very recent investigation revealed that deficiency in NatA-
mediated Nt-acetylation most likely causes misfolding of a
variety of NatA substrates thus suggesting Nt-acetylation to
be a general factor mediating protein folding [162–164]. The
(patho)physiological importance of Nt-acetylation only re-
cently emerged, as the Ogden syndrome was found to be
caused by a NAT mutation [59, 165, 166]. Clinical features of
the Ogden syndrome include postnatal growth failure, de-
velopmental delays and death during infancy [166]. The ge-
netic cause of the Ogden syndrome, a Ser37Pro mutation in
NAA10, results in impaired enzymatic activity andNatA com-
plex formation [59, 165]. Further characterization of Naa10
Ser37Pro revealed specific downstreamNt-acetylation defects
in vivo as well as abnormal cell migration and proliferation
capacity of affected fibroblasts [165]. In addition, de novomis-
sense mutations in the NAA10 gene have been identified in
two independent cases of global developmental delay [167],
and a truncated Naa10 protein is implicated in Lenzmicroph-
thalmia syndrome [168]. Finally, several NATs, in particular
the NatA subunits Naa10 and Naa15, are dysregulated in
various human cancers [169]. In most types of cancers in-
vestigated, NAT-overexpression mediates increased survival
and proliferation of cancer cells. Because of its implication
in human disease and cancer, NatA is a potential drug tar-
get and specific NAT-inhibitors are under development [170].
The role of Nt-acetylation during development is reviewed in
another article in this issue [171].
The main feature of protein fatty acylation is to provide
the target protein with hydrophobicity thus promoting mem-
brane binding.Nt-palmitoylation is quite rare, but seems to be
an important protein modification involved in signal trans-
duction [108]. Indeed, the hydrophobic nature of palmitoyl
has been found indispensable for the strength of Shh sig-
naling [114]. A reduced pattering activity in mouse limb is
observed for Shh in the absence of Nt-palmitoylation, while
in D. melanogaster the Hh is found inactive [172, 173]. In
humans, an uncontrolled activation of Hh signaling path-
way is linked to different types of cancer [174]. Compared to
Nt-palmitoylation, Nt-myristoylation is more prevalent and
the common denominator for many proteins modified in
this way is their participation in cellular signaling pathways
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Table 2. Protein N-terminal modifications sorted by the N-terminal sequence
AA1 AA2 % abundance
in pos. 2b)
Nt-modificationc) N-terminus Enzyme Substrate
Met Ala 23.1 Ac Met-Ala- NatE/F
iMet exc. Met-Ala- MetAP1/2
Ac Ala- NatA
Methyl Ala-Pro-Lys- NTMT1/2 DDB2, SET
Arga) 4.5 Ac Met-Arg- NatE/F
Asn 3.2 Ac Met-Asn- NatB
Asp 5.7 Ac Met-Asp- NatB
iMet exc. Met-Asp- ND Cyto. -actin
Ac Asp- Naa10 Cyto. -actin
Cys 0.9 iMet exc. Met-Cys- MetAP1/2
Ac Cys- NatA
Palm Cys- Hhat Shh
Gln 2.3 Ac Met-Gln- NatB/F
Glu 9.6 Ac Met-Glu- NatB
iMet exc. Met-Glu- ND Cyto. -actin
Ac Glu- Naa10 Cyto. -actin
Gly 7.9 Ac Met-Gly NatF
iMet exc. Met-Gly- MetAP1/2
Ac Gly- NatA
Methyl Gly-Pro-Lys- NTMT1/2 CENP-A/B
Myr Gly- NMT1/2
Palm Gly- PAT GS
Hisa) 1.0 Ac Met-His- NatE/F
Ile 1.5 Ac Met-Ile- NatC/F
Leu 5.3 Ac Met-Leu- NatC/E/F
Lys 4.3 Ac Met-Lys- NatE/F
Met 1.6 Ac Met-Met- NatE/F
Phe 1.8 Ac Met-Phe- NatC
Pro 5.4 iMet exc. Met-Pro- MetAP1/2
Methyl Pro-Pro-Lys- NTMT1/2 RB
Ser 11.4 Ac Met-Ser- NatE/F
iMet exc. Met-Ser MetAP1/2
Ac Ser- NatA
Ac Ser-Gly-Arg- NatD H2A
Ac Ser-Gly-Gly- NatD H4
Methyl Ser-Pro-Lys- NTMT1/2 RCC1
Thr 4.4 Ac Met-Thr- NatE/F
iMet exc. Met-Thr- MetAP1/2
Ac Thr- NatA
Trp 1.3 Ac Met-Trp- NatC
Tyr 0.8 Ac Met-Tyr- NatE/F
Val 4.0 Ac Met-Val- NatE/F
iMet exc. Met-Val- MetAP1/2
Ac Val- NatA
a) Arg and His presumable follow the same modification pattern as Lys.
b) Distribution based on human proteins listed in Swiss-Prot 56.0.
c) Most likely, N-terminal propionylation follows the same patterns as N-terminal acetylation.
AA, amino acid; ND, Not determined
[175]. This involves subcellular targeting, protein-protein and
protein-membrane interactions [4] and possibly protein struc-
tural stability [176].
To date, protein specific consequences of Nt-methylation
have only been described for a subset of eukaryotic proteins
[121–125]. Similar to NatA subunits, aberrant expression of
NTMT1 has been reported in numerous cancer types. How-
ever, the functional understanding of NTMT1’s role in can-
cer progression and prognosis is limited making it a focus
of research [7]. Nt-methylation is inter alia involved in reg-
ulating protein function, specifically protein-DNA interac-
tions, and several studies have suggested a role in chromatin
conformation and segregation [121, 123, 125, 128] and DNA
repair [122]. Nt-methylation of RCC1 (regulator of chromo-
some condensation 1) was shown to promote associationwith
chromatin. Both methylation-defective RCC1 mutants and
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Figure 2. Substrate specificity of N-terminal modifying enzymes. Proteins are synthesized with an initiator methionine (iMet). The iMet can
remain at the N-terminus (blue) or be removed by MetAPs (yellow). A retained iMet can undergo Nt-acetylation (red) by one of four NATs
(NatB/NatC/NatE/NatF), depending upon the subsequent amino acid (listed). Following iMet removal, the N-terminal amino acid residue
can become Nt-acetylated, Nt-myristoylated, Nt-palmitoylated or Nt-methylated (green). It is not known whether Nt-ubiquitylation (grey)
takes place on iMet and/or the exposed amino acid residue following iMet removal. A consensus sequence for Nt-ubiquitylation has not
been established. *For Met-Asp and Met-Glu of mammalian cytoplasmic -actin and -actin, respectively, iMet excision is catalyzed by an
unidentified aminopeptidase. †Asp and Glu of mammalian cytoplasmic -actin and -actin, respectively, are Nt-acetylated by Naa10. ǂCys
is post-translationally Nt-palmitoylated after generation of protein neo-N-termini by endopeptidases.
NTMT1 knockdown results in decreased affinity for DNA,
which causes mislocalization from chromatin and subse-
quent defects in spindle pole organization and chromosome
missegregation [121,128]. RCC1 binds to chromatin through
a bimodal attachment mechanism, where the methylated N-
terminus associates with negatively charged DNA and the
main protein body binds to histones H2A/H2B [121,126].
Due to limited knowledge on the Nt-ubiquitylome, the bi-
ological understanding of Nt-ubiquitylation remains limited.
Vittal et al. proposed that Nt-ubiquitylation could be linked to
protein quality control on stalled ribosomes, where it primes
nascent polypeptides for subsequent polyubiquitylation [145].
On the contrary, Ube2w is predicted to harbor a nuclear lo-
calization signal and may therefore regulate nuclear proteins
[177]. Ube2w has been found to be overexpressed in certain
human cancers [178]. In that regard, Mittag and Marzahn
have suggested that Nt-ubiquitylation could be involved in
maintaining homeostasis of important regulatory proteins
[179].
9 Discussion
The majority of eukaryotic protein N-termini is chemically
modified by at least one of the many Nt-modifying enzymes.
Multiple factors determine whether and how a given protein
substrate will be modified including: i) the N-terminal amino
acid sequence of the protein relative to the different specifici-
ties of themodifying enzymes, ii) the availability and subcellu-
lar localization of the different Nt-modifying enzymes under
given conditions, and iii) the availability of the donor sub-
strate (e.g., acetyl-CoA, SAM, etc.). Some of the Nt-modifying
enzymes have overlapping substrate specificities (Table 2), so
what governs the modification faith of individual proteins?
First, it is important to distinguish between co- and post-
translational N-terminal modifications (Fig. 3). The enzymes
capable of contacting the nascent N-termini, on the ribosome
like MetAPs, NATs and NMTs, will be the first to target the
pool of substrates. The non-ribosomal enzymes are however
only capable of modifying the substrates not modified co-
translationally, in addition to the neo-N-termini generated
by endopeptidases. For instance, the Ser-Pro- or Gly-Pro-
N-termini that are never co-translationally Nt-acetylated by
NATs [62] are specifically targeted by NTMT-mediated post-
translational Nt-methylation [6, 125]. The substrate specifici-
ties of the NTMTs have possibly evolved to prefer those N-
termini that are available (thus those that have not beenmod-
ified by co-translationally acting NATs or NMTs).
This simple picture of mutually exclusive modifications
may be true given that all Nt-modifications are irreversible;
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Figure 3. Overview of co- and post-translational N-terminal modifications. Co-translational protein modifications (left) taking place on
the ribosomes include iMet excision, Nt-acetylation, Nt-propionylation, Nt-myristoylation or Nt-palmitoylation. Post-translational modifi-
cations (right) include Nt-methylation, Nt-palmitoylation or Nt-acetylation. Regarding Nt-ubiquitylation, it is uncertain whether it is a co-
or post-translational event. Listed in relation to each modification are the responsible enzymes. The arrows are weighed according to the
presumed extent of the individual modifications.*Preceding post-translational Nt-palmitoylation of Cys, a signal sequence is removed by
endopeptidases thus generating neo-N-termini. †The case of mammalian cytoplasmic -actin and -actin (Met-Asp and Met-Glu, respec-
tively) involves co-translational Nt-acetylation of iMet, presumably by NatB, followed by post-translational Ac-iMet excision by an unknown
aminopeptidase and finally Nt-acetylation by Naa10.
one modification event will normally block for further mod-
ifications, except in the case of iMet excision. However, are
these N-terminal modifications truly irreversible? In most
cases the Nt-modifications are probably permanent through-
out the lifetime of a protein. However, it is plausible to
think that at least a small fraction of the Nt-modified pro-
teins are subjected to hitherto unidentified Nt-demodifying
enzymes that act to regulate critical substrates. If so, Nt-
modifications may serve a dynamic regulatory role for pro-
tein function, and different modifications may be inter-
changeable to serve specific functions. Substrates suggested
to be subjected to Nt-demodifying enzymes include His-
tone H4 [180] and myosin regulatory light chain 9 (MYL9)
[7, 130].
Among the enzymes acting on the ribosome, there may
be competition for the emerging polypeptides. Sterically, the
different modifying enzymes are unlikely to bind simultane-
ously to the ribosome [96]. Thus a specific order of modifi-
cation events could be envisioned. However, this does not
always seem to be the case. For example, competition be-
tween co-translational Nt-acetylation and Nt-myristoylation
has been observed and found to depend on amino acid se-
quences beyond the targeted Gly residue [181]. Further, a re-
cent study suggested a kinetic competition between MetAPs
and NATs: If the NAT (NatE) acts first, then the iMet will be
retained since furtherMetAP action is precluded by the acety-
lated iMet, while if the MetAP acts first, then iMet excision
will occur and could potentially be followed by downstream
Nt-acetylation by NatA [182].
Within a single class of enzymes like the NATs there is
an apparent overlap in the in vitro substrate specificity; NatC,
NatE and NatF all Nt-acetylate Met-starting N-termini with
an aliphatic or hydrophilic amino acid in the second posi-
tion (Fig. 2). This could perhaps be explained by special-
ization towards different types of substrates in vivo. NatC
co-translationally acetylates hydrophobic N-termini that are
normally never subjected to iMet excision (Met-Ile-, Met-
Leu-, etc.). NatE (Naa50 bound to Naa15 and Naa10) co-
translationally acetylates proteins that are often subjected to
iMet excision (Met-Ala-, Met-Val-, etc.), but when targeted
by NatE will retain its iMet in its acetylated state [182].
NatE/Naa50 may also have a post-translational role in the
cytosol or nucleus towards Met-Leu- starting N-termini and
similar substrates [50, 60]. NatF, on the other hand, was very
recently revealed to specifically Nt-acetylate transmembrane
proteins [58]. This unique activity is most likely mediated
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in a post-translational manner via the membrane anchoring
properties of NatF.
Significant knowledge on the different N-terminal modi-
fications and their responsible enzymes has been gained in
the past decades. N-terminal modifications undoubtedly have
a pivotal role in protein regulation and cellular signaling.
However, future efforts are required to fully comprehend the
functional role and the in vivo impact of these modifications,
which includes understanding their dynamics, potential re-
versibility and interplay. Dysfunction or dysregulation of N-
terminalmodifying enzymes is implicated in humandiseases
including cancer, and this further stresses the importance of
continuing research efforts in this field.
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